Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Mar 05, 2021 10:24am
95 Views
Post# 32727320

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Maybe partnerships are coming soon

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Maybe partnerships are coming soonI think the discussion about that aspect of the hire is missing the forest because of the trees. If the new person only speaks ancient greek but can still negotiate partnerships which benefit shareholders long term interests, then I will be happy. The hire itself is telling us positive things about what the company is likely seeing. 

palinc2000 wrote: You dont agree that they should hire the best available and not necessarily stick to the requirement that the candidate be bilingual,,?


SPCEO1 wrote: The discussion surrounding this job posting is known in the news business as "burying the lede" or ignoring the main point of the story, which is they are thinking about partnerships, anticipating them and preparing for them. While this has certainly been true for a while, this is the first public acknowledgement of it. And the implications are notable - their confidence in their clinical programs is high and outside validation of those programs could be on the horizon. And then there is the potential monetization of some of the potential of those programs. It suggests to me they have already gotten inquiries.
palinc2000 wrote: The candidate interaction with the staff will be minimal,,,I am sure the requirement is just there to be legally and  politically correct but they will be free to hire the best even if he/she does not speak French


scarlet1967 wrote: I think they need to show some flexibility to get the best person/persons.
I am sure in the international corporate biotech  most people speak English regardless of geographic.
If they have any intention (which they should in case they are presented with a sweet deal) to explore possible partnership in the near or even distance future they need to keep that door open rather than playing the devil's advocate.
We don't want them to rush to another rushed deal  I have seen so many companies which have managed closing attractive deals. each and every one of them have a partnership section in their website.
As many mentioned earlier a potential partnership brings funds, de-risk the R&D program/programs and bring more credibility to the programs and the whole company.
If the deal is good the money left on the table is well worth it IMO.
palinc2000 wrote:

 Its because the candidate will be based in the Montreal HO

 

scarlet1967 wrote: I don't think Leah Gibson the head of IR department is bilingual, she was hired based on her industry credentials therefore if the right person with right skills applies for the jobs the language requirement is of less importance rather than considering the overall experience.
I think and I did suggest to Leah to upgrade the website and if they are thinking about potential future partnership add a section to the website.
They don't need to commit but they can if they choose so at anytime.
Leah will be based in the Boston area, and report to Philippe Dubuc, Senior Vice President and Chief Financial Officer.

 

 


 

 

 




<< Previous
Bullboard Posts
Next >>